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INTRODUCTION 
Hepatocellular  carcinoma  (HCC)  is  the  most  common  histological  type  of  
primary  liver  carcinoma.  HCC  is  a  major  health  problem  worldwide  due  to  
its  high  incidence  and  high  rates  of  mortality. 
• Liver  is  a  common  site  of  metastasis  from  many  primary  sites  due  to  
rich  portal  and  systemic  venous  supply.  Thus,  metastatic  cancer  is  the  most  
common  malignant  tumour  in  adult  liver. 
• The  distinction  of  liver  metastatic  tumour  from  HCC  may  present  a  
diagnostic  challenge  that  carries  an impact  on  subsequent  prognostication  and  
therapeutic  management.   
• The  morphology  is  used  to  establish  a  differential  diagnosis  and  then    
histochemical  and  immunohistochemical  studies  are  used  to  refine  the  
diagnosis.  Immunohistochemistry  is  helpful  when  morphology  and  
identification  of  secretory  substances  fail.   
• Among  immunohistochemical  markers,  Hep  par-1  has  been  reported  
as  most  sensitive  and  specific  immunohistochemical  marker  for  HCC. 
• Cytokeratins  7,  19  and  20  were  absent  from  most  hepatocellular  
carcinomas  but  positive  in  many  adenocarcinomas,  including  
cholangiocarcinomas. 
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• Tissue  microarray  is  a  recent  innovation  in  the  field  of  pathology.  A  
microarray  contains  many  small  representative  tissue  samples  from  hundreds  
of  different  cases  assembled  on  a  single  histologic  slide,  and  therefore  
allows  high  throughput  analysis  of  multiple  specimens  at  the  same  time. 
•   With  this  technology,  tissue  samples  in  the  microarrays  are  
amenable  to  a  wide  range  of  techniques,  including  histochemical  stains,  
immunologic  stains  with  either  chromogenic  or  fluorescent  visualization,  in  
situ  hybridization  and  even  tissue  micro-dissection  techniques 
• This  method  has  proven  to  be  extremely  efficient,  of  shorter  duration,  
and  cost  effective,  especially  with  expensive  reagents.
[1,2,3,4]
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AIMS AND OBJECTIVES 
• To  differentiate  and  to  study  the  pattern  of  IHC  markers  like  Hep-
Par 1, CK7,  CK19 and CK20  in  primary  hepatocellular  carcinoma, 
cholangiocarcinoma  and  metastatic  secondaries  from  colorectal  region in  
liver. 
• To  demonstrate  use  of  manual  tissue  microarray  technique  and  its  
advantages  of  the  same  in  IHC.  
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REVIEW  OF  LITERATURE 
Hepatocellular  carcinoma  (HCC)  is  known  for  its  histomorphologic  
heterogeneity.  To  differentiate  HCC  from  their  mimics  is  often  a  
challenging  issue  in  histopathology.  The  Reasons  for  this  are:  a)  Variety  of  
neoplasms  that  can  arise  from  the  hepatocytes,  b)  The  liver  is  a  target  
organ  for  metastases  that  can  mimic  variants  of  primary  hepatocellular  
carcinoma,  and  c)  The  limitations  of  serum  Alpha-fetoprotein  (AFP)  in  
differentiating  the  poorly  differentiated  HCC  from  intrahepatic  
cholangiocarcinoma  (CC)  and    metastatic  carcinomatous  deposits  from  
elsewhere. 
Various  immunohistochemical  markers  have  been  used  for  the  identification  
of  these  tumors  that  include  α-1-antitrypsin,  carcinoembryonic antigen  (CEA),  
factor  XIIIa,  ferritin,  and  albumin.  However,  their  use  to  differentiate  HCC 
from  other  neoplasms  has  been  limited.
[6,7,8,9,10] 
Among  immunohistochemical  markers,  Hep  Par-1  has  been  used  in  various  
studies  and  reported  as  the  most  sensitive  and  specific  immunohistochemical  
marker  for  HCC.  CK 7, CK 19 for  intrahepatic cholangiocarcinoma  and  CK 20  
for  Metastatic  Adenocarcinomatous  deposit  in  liver  from  colorectal  
region.
[1,11,12,13] 
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EMBRYOLOGY 
Liver  primordium  appears  in  the  middle  of  3
rd
    week,  as  outgrowth  of  the  
endodermal  epithelium  at  the  distal  end  of  the  foregut.  From  this  outgrowth,  
the  hepatic  diverticulum,  or  liver  bud  is  formed  and  penetrates  the  septum  
transversum. 
  While  hepatic  cells  continue  to  penetrate  the  septum,  the  connection  
between  the  hepatic  diverticulum  and  the  foregut  (duodenum)  narrows,  
forming  the  bile  duct.  A  small  ventral  outgrowth  arises  from  the  bile  duct,  
and  which  gives  rise  to  the  gallbladder  and  the  cystic  duct.   
During  further  development,  epithelial  liver  cords  intermingle  with  the  
vitelline  and  umbilical  veins,  and  thus  forms  hepatic  sinusoids.    The  
mesoderm  of  the  septum  transversum  forms  the  hematopoietic  cells,  Kupffer  
cells  and  connective  tissue  cells. 
After  the  invasion  of  hepatocytes  into  the  entire  septum  transversum,  the  
organ  bulges  caudally  into  the  abdominal  cavity,  and  the  mesoderm  of  the  
septum  transversum  lying  between  the  liver  and  the  foregut  and  the  liver  
and  ventral  abdominal  wall  become  membranous,  and  forms  the  lesser  
omentum  and  falciform  ligament  respectively.   
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Anatomy  
 
Fig  1  Gross  anatomy  of  the  liver 
The  Liver  is  the  largest  single  wedge  shaped  organ  in  the  human  body.  In  
an  adult,  it  weighs  about  1400  to  1600  kilograms  and  located  in  the  right  
hypochondrium,  behind  the  lower  ribs.  The  liver  is  divided  into  four  lobes:  
the  right  (the  largest  lobe),  left,  quadrate  and  caudate  lobes.   
The  arterial  supply  of  the  liver  is  by  the  portal  vein  and  hepatic  artery.    
Venous  drainage  is  by  the  hepatic  vein.  It  is  connected  to  the  diaphragm  
and  abdominal  walls  by  five  ligaments.  The  main  functions  of  the  gall  
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bladder  are  the  storage,  concentration,  acidification  and  delivery  of  bile  to  
small  intestine. 
Histology 
 
Fig  2  Histology  of  the  liver 
Liver  is  divided  into  many  functional  units  called  Lobules  and  these  are  
hexagonal  in  shape.  Lobules  are  formed  of  tightly  packed,  plates  of  
epithelial  cells  called  as hepatocytes  radiating  from  a  central  vein.  The  outer  
surface  of  the  liver  is  covered  by  a  capsule  composed  of  fibrous  tissue  
called  Glisson's  capsule. 
Hepatocytes  are  large  polyhedral  cells  with  round  nuclei  with  peripherally  
dispersed  chromatin  and  prominent  nucleoli.  The  nuclei  shows  pleomorphism  
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and  > 50%  of  the  hepatocytes  are  diploid  and  some  are  even    polyploid.  
Binucleate  cells  are  also  seen  in  normal  liver. 
The  abundant  cytoplasm  is  eosinophilic  with  few  basophilic  granules due to 
presence  of  numerous  mitochondria  and  rough  endoplasmic  reticulum  
respectively.  The  sinusoids  are  lined  by  flattened  endothelial  lining  cells.   
The  portal  triad  contains  three  main  structures.  They  are  the  branch  of  the  
hepatic  portal  vein,  smaller  diameter  thick-walled  vessels  are  terminal  
branches  of  the  hepatic  artery  and  the  bile  ductules. 
Between  the  hepatocytes,  bile  canaliculi  are  present  which  drains  into    
collecting  ducts  (canals  of  Hering).  These  drains  into  the  bile  ductules  
which  in  turn  drains  into  intrahepatic  ducts  and  into  the  right  and  left  
hepatic  ducts,  the  common  hepatic  duct  and  then  to  the  duodenum  via  the  
common  bile  duct.  The  portal  tracts  are  often  called  as  portal  triads.  
Lymphatics  are  also  present  in  the  portal  tracts,  but  since  their  walls  are  
delicate  and  often  collapsed  they  are  not  easily  made  out. 
The  layer  of  hepatocytes  immediately  bordering  the  portal  triad  is  known  as  
the  limiting  plate.  Between  the  anastomosing  plates  of  hepatocytes,  there are  
sinusoids    which  receives  blood  from  both  the  portal  and  hepatic  arterial  
systems.     
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Physiology 
The  functions  of  the  liver  can  be  classified  broadly  as  metabolic,  synthetic,  
storage,  catabolic,  and  excretory. 
METABOLIC  FUNCTIONS: 
Liver  plays  several  roles  in  carbohydrate  metabolism. It  synthesizes  and  
stores  glycogen  via  glycogenesis  and  glycogenolysis.  It  is  also  responsible  
for  gluconeogensis  and  cholesterol  synthesis. 
SYNTHETIC  FUNCTIONS: 
Liver  synthesize  plasma  proteins  that  includes  albumin,  coagulation  factors(I, 
II,  V,  VII,  IX,  X,  XI),  complements,  acute  phase  reactants,  and  binding  
proteins  for  vitamin  A,  iron  and  copper. 
STORAGE  FUNCTIONS: 
Liver  stores  various  substances  like  glycogen,  copper,  iron,  lipid-soluble  
vitamins( vitamin A,  D),  iron,  copper  and  triglycerides. 
CATABOLIC  FUNCTIONS: 
Liver  catabolises  endogenous  substances,  hormones,  serum  proteins,  and  
plays  an  vital  role  in  the  detoxification  of  drugs. 
EXCRETORY  FUNCTIONS: 
Bile  is  the  primary  excretory  product  of  the  liver  which  is  a  mixture  of  
bile  acids,  conjugated  bilirubin,    cholesterol,  phospholipids,  and  
electrolytes.
[14,15,16] 
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Pathology  of  Hepatocellular  carcinoma 
Many  etiologic  factors  are implicated  in  etiopathogenesis  of  HCC,  most 
important  being  HBV  and  HCV infection,  and  association   with  cirrhosis.  
Genesis  of  HCC  is  linked  to  prolonged  infection  with  HBV.  The  evidence  
in  support  is  both  epidemiologic  and  direct.  The  incidence  of  HBsAg  
positivity  is  higher  in  HCC  patients.  There  is  more  direct  evidence  of   
integration  of  HBV-DNA  genome  in  the  genome  of  tumour  cells  of  HCC. 
Conditions  Associated  with  Hepatocellular  Carcinoma  
[17] 
1.Cirrhosis  
Alcohol High 
Hepatitis  C High 
Hepatitis  B High 
Autoimmune  chronic  active  hepatitis High 
Cirrhosis  due  to  non  alcoholic  fatty  
liver  disease 
Moderate 
Crytogenic  cirrhosis Moderate 
Primary  Biliary  Cirrhosis Low 
2.Metabolic  diseases  
alpha1-Antitrypsin  deficiency Moderate 
Ataxia  telangiectasia   Moderate 
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Types  1  and  3  glycogen  storage  
disease 
Moderate 
 
Galactosemia Moderate 
Citrullinemia Moderate 
Porphyria  cutanea  tarda   Moderate 
Wilson's  disease Low 
 
3.Environmental  
Thorotrast   Moderate 
Androgenic  steroids   Moderate 
Cigarette  smoking   Moderate 
Aflatoxin   Moderate 
 
 Long-standing  HCV  infection  has  emereged  as  a  major  factor  in  the  
etiology  of  HCC,  generally  after  more  than  30 years  of  infection.  The  
patients  having  anti-HCV  and  anti-HBc  antibodies  together  have  three  times   
higher  risk  of  developing  HCC  than  in  those  with  either  antibody  alone.  
HCV  infection  after  a  long  interval  produces  cirrohosis  more  often  prior  to  
development  of  HCC,  while  in  HCC  following  HBV  infection  half  the    
cases  have  cirrohosis  and  remainder  have  chronic  hepatitis. 
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It  is  also  possible  that  HBV  and  HCV  infection  act  synergistically  to  
predispose  to  HCC.   
Cirrhosis  of  all  etiologic  types  is  more  commonly  associated  with  HCC  but  
the  most  frequent  association  is  with  macronodular  post-necrotic  cirrhosis.  
The  mechanism  of  progression  to  HCC  appears  to  be  chronic  regenerative  
activity  in  cirrhosis,  or  that  the  damaged  liver  in  cirrhosis  is  rendered  
vulnerable  to  carcinogenic  influences.  Liver  cell  dysplasia  identified  by  
cellular  enlargement,  nuclear  hyperchromatism  and  multinucleate  cells,  is  
found  in  60%  of  cirrhotic  livers  with  HCC  and  in  only  10%  of  non-
cirrhotic  livers.  It  has  been  observed  that  alcoholics  have  about  four-fold  
increased  risk  of  developing  HCC.  It  is  possible  that  alcohol  may  act  as  
co-carcinogen  with  HBV  or  HCV  infection,  but  alcohol  does  not  appear  to  
be  a  hepatic  carcinogen  per  se.   
An  important  mycotoxin,  aflatoxin  B1, produced  by  a  mould  Aspergillus  
flavus,  is  carcinogenic;  it  may  act  as  a  co-carcinogen  with  hepatitis  B  or  
may  suppress  the  cellular  immune  response.  A  number  of  chemical  
carcinogens  can  induce  liver  cancer  in  experimental  animals.  These  include  
butter-yellow  and  nitrosamines  used  as  common  food  additives.  
 Limited  role  of  various  other  factors  in  HCC  has  been  observed.  These  
include  the  following:  i)  haemochromatosis;  ii)  α-1-antitrypsin  deficiency;  iii)  
prolonged  immunosuppressive  therapy  in  renal  transplant  patients;  iv)  other  
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types  of  viral  hepatitis;  v)  tobacco  smoking;  and  vi)  parasitic  infestations  
such  as  clonorchiasis  and  schistosomiasis. 
Gross Pathology of HCC 
The  background  liver  shows  cirrhosis  in  the  majority  of  cases.  Tumors  can  
be  classified  as  massive  when  a  solitary  large  mass  is  seen,  nodular  when  
multiple  discrete  nodules  are  seen,  and  diffuse  when  multiple  small  
indistinct  nodules  are  seen.  Tumors  less  than  2  cm  in  diameter  are  referred  
to  as  small  HCC;  these  small  tumors  usually  lack  gross  vascular  invasion,  
necrosis,  or  hemorrhage.  Tumors  are  generally  soft  and  may  be  paler  than  
the  adjacent  liver  or  bile  stained.    Irregular  borders  and  satellite  nodules  
can  be  present.  HCC  has  a  tendency  for  vascular  invasion.  Portal  and  
hepatic  veins  can  be  involved. 
The  grading  of  HCC  is  based  on  differentiation  of  tumor  and  is  based  on  
the  system  developed  by  Edmondson  and  Steiner  in  1954.  Well-
differentiated  tumors  show  a  pseudoacinar  or  thin  trabecular  pattern  and  
mild  nuclear  atypia.  Most  of  the  tumors  are  less  than  3  cm,  and  fatty  
change  is  often  present(Figure 11).  Moderately  differentiated  tumors  have  
more  cytologic  and  architectural  variability  with  wider  trabeculae  and  more  
pronounced  cytologic  atypia.  Multinucleated  and  giant  tumor  cells  can  be  
seen  focally(Figure 12).  Poorly  differentiated  tumors  often  show  a  solid  
growth  pattern  accompanied  by  moderate  to  marked  nuclear  pleomorphism 
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(Figure 13).    Undifferentiated  tumors  also  show  a  solid  growth  pattern  with  
no  apparent    hepatocellular  differentiation  and  may  include  sarcomatoid  
components.
[18] 
Pathogenesis  of  Cholangiocarcinoma 
The  pathogenesis  of  cholangiocarcinoma  is  poorly  understood,  the  incidence  
and  mortality  is  in  increasing  trend.
[19]  
 It  is  often  diagnosed  late  and  
survival  is  poor.  About  15-20%  of  liver  and  bile  duct  cancers  are  
cholangiocarcinoma.  Like  gallbladder  cancers  the  incidence  increases  with  
age.  The  term  cholangiocarcinoma  includes  intrahepatic,  perihilar  and  distal  
extrahepatic  tumours  of  biliary  tracts.  The  perihilar  tumours  involving  the  
bifurcation  of  hepatic  ducts  also  termed  as  Klatskin  tumour,  from  Klatskin’s  
original  description  in  1965.   
The  perihilar  bile  duct  tumours  were  classified  by  Bismuth  et  al.  as  
tumours  below  the  confluence  of  the  left  and  right  hepatic  ducts  (type  I),  
tumours  reaching  the  confluence(typeII),  tumours  occluding  the  common  
hepatic  duct  and  either  the  right  or  left  duct  (types  IIIa  and  IIIb,  
respectively),  and  tumours  that  are  multicentric  or  that  involve  the  
confluence  and  both  the  right  and  left  hepatic  ducts(type  IV).
[20]
 
Most  cholangiocarcinomas  involve  perihilar  and  distal  extrahepatic  bile  
ducts. 
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RISK  FACTORS
[21]
   
1. Hepatolithiasis 
2. Liver  flukes 
3. Biliary  cystic  disease 
4. Primary  sclerosing  cholangitis 
5. Radionucleotides 
6. Chemical  carcinogens   
The  evolution  of  cellular  changes  most  probably  can  be  described  as  a  
multistep  sequential  progrssion  of  metaplasia,  dysplasia  and  finally  neoplasia.  
Conversion  of  normal  to  malignant  bile  duct  tissue  probably  requires  a  
number  of  successive  mutations.  Oncogenes  are  K-ras,  c-myc,  c-neu,  c-erb-
b2  and  c-met.  Tumour  suppressor  genes  are  p53  and  bcl-2.
[22,23]
 
Gross  Pathology.  The  three  macroscopic  types  of  Intrahepatic 
cholangiocarcinoma:  mass  forming,  periductal  infiltrating,  and  intraductal.   
Mass  forming  is  the  most  common  appearance  of  intrahepatic  
cholangiocarcinoma  and  is  characterized  by  a  localized  tumor  with  a  distinct  
border  that  grows  radially  without  periductal  or  intraductal  spread.  The  
periductal-infiltrating  type  infiltrates  along  the  bile  duct  and  is  often  
associated  with  stricture  and  involvement  of  periductal  connective  tissue.  
Both  these  types  are  usually  firm,  white-tan  lesions  because  of  a  dense  
fibrous  stroma.  Advanced  cases  can  show  mixed  patterns  of  growth. 
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Microscopic  Features.  Majority  (>95%)  of  these  tumors  are  
adenocarcinomas.  The  well-differentiated  tumors  show  tubular,  papillary,  and  
cord-like  patterns,  and  cytologic  atypia  can  be  minimal.  Intracytoplasmic  
lumina,  focal  cribriform  architecture,  nuclear  stratification,  and  intraluminal  
cellular  debris  favor  carcinoma  over  a  benign  process.  Nucleoli  are  often  
less  prominent  compared  with  HCC.  Mucin  can  be  demonstrated  in  most  
cases.  A  prominent  desmoplastic  stroma  is  characteristic  of  
cholangiocarcinoma.  Occasionally,  the  tumor  cells  form  small  narrow  tubular  
structures  resembling  ductules  or  canals  of  Hering 
METASTATIC  LIVER  DISEASE  
Metastatic  tumours  are  the  most  common  malignant  liver  lesion  in  adults.
[24] 
  By  haematogenous,  lymphatic  or  transperitoneal  spread,  almost  all  
malignant  neoplasms  and  haematological  malignancies,  can  secondarily  
involve  the  liver  and  cause  metastatic  disease.
[25]
 
In  case  of  liver  metastasis,  the  primary  tumour  most  frequently  is  located  
in  colon,  pancreas,  stomach,  breast,  oesophagus,  genitourinary  organs
[26]
.  
Lung  cancer  can  metastasize  to  liver.
[27]
  Adenocarcinoma  was  the  most  
frequent  histological  type  of  metastases  in  liver.  Lymphoma  constituted  
0.4%  of  all  tumours.
[28,29]
  In  children,  neuroblastoma,  nephroblastoma  and  
rhabdomyosarcoma are  the  most  frequent  sources  of  metastases  to  the  
liver.
[30]  
  The  liver  metastases  can  occur  in  patients  with  Hodgkin’s  
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lymphoma  and  non-Hodgkin’s  lymphoma  at  the  time  of  diagnosis and even  
leukemias  can  also  involve  the  liver.
[27] 
Diagnosis  of  malignant  melanoma
[26]
  is  very  difficult  due to variable  
morphological  features  and  using  specific  IHC  markers  gives  the  diagnosis.   
 To  identify  the  metastasis  from  breast  primary  tumour,  gross  cystic  disease  
fluid  protein  fraction-15  (GCDFP-15)  and/or  mammaglobin  can  be  used.  
Breast  cancers  of  luminal  molecular  type  express  oestrogen  (ER)  and  
progesterone  receptors  (PR). 
   Use  of  LCA  (leukocyte  common  antigen)  can  differentiate  HCC  from  
haematological  neoplasms.  The  CK5/6  and  CK  34betaE12  in  association  
with  strong  nuclear  reactivity  with  p63  protein  are  useful  to  diagnose  
squamous  cell  carcinoma.
[31,32]
 
Metastatic  colorectal  carcinomas  can  be  recognised  by  diffuse  intensive  
cytoplasmic  expression  of  CK20  and  nuclear  expression  of  CDX2.
[33,34] 
Neuroendocrine  tumours  are  characterised  by  strong  cytoplasmic  expression  
of  chromogranin  A  and  synaptophysin  and  negativity  for  Hep  Par  1.   
PAX-2  is  used  as  marker  of  metastatic  renal  cell  carcinoma. 
 
 
 
 
xxxiv 
 
WHO  HISTOLOGICAL  CLASSIFICATION  OF  TUMOURS  OF  LIVER  
AND  INTRAHEPATIC  BILE  DUCTS  - 2010 
Epithelial  tumours 
Benign 
  Hepatocellular  adenoma 
  Intrahepatic  bile  duct  adenoma 
  Intrahepatic  bile  duct  cystadenoma 
  Biliary  papillomatosis 
  Focal  nodular  hyperplasia 
Malignant 
  Hepatocellular  carcinoma 
  Bile  duct  cystadenocarcinoma 
  Intrahepatic  cholangiocarcinoma 
  Hepatoblastoma 
  Combined  hepatocellular  and  cholangiocarcinoma 
  Undifferentiated  carcinoma 
Non-epithelial  tumours 
Benign 
  Angiomyolipoma 
  Haemangioma 
  Infantile  haemangioendothelioma 
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  Lymphangioma  and  lymphangiomatos  is 
Malignant 
  Angiosarcoma 
  Epithelioid  haemangioendothelioma 
  Rhabdomyosarcoma 
  Embryonal  sarcoma 
  Others 
Miscellaneous  Tumours 
  Kaposi  sarcoma 
  Solitary  fibrous  tumour 
  Teratoma 
  Yolk  sac  tumour 
  Carcinosarcoma 
  Rhabdoid  tumour 
Haemopoietic  and  lymphoid  tumours 
Secondary  tumours 
Epithelial  abnormalities 
  Dysplastic  nodules 
  Bile  duct  abnormalities 
  Liver  cell  dysplasia 
  Intraepithelial  carcinoma 
xxxvi 
 
  TNM  Staging  Scheme  for  Carcinoma  of    Liver  and  Intra  hepatic  bile  
ducts  (AJCC 2010) 
PRIMARY  TUMOR  (T) 
TX  :  Primary  tumor  cannot  be  assessed 
T0  :  No  evidence  of  primary  tumor 
T1  :  Solitary  tumor  without  vascular  invasion 
T2  :  Solitary  tumor  with  vascular  invasion  or  multiple  tumors  none  >5  cm 
T3  :  Multiple  tumors  >5  cm  or  tumor  involving  a  major 
branch  of  the  portal  or  hepatic  vein(s) 
T4  :  Tumor(s)  with  direct  invasion  of  adjacent  organs  other  than  the  
gallbladder  or  w  ith  perforation  of  visceral  peritoneum 
REGIONAL  LYMPH  NODES  (N) 
NX  :  Regional  lymph  nodes  cannot  be  assessed 
N0  :  No  regional  lymph  node  metastasis 
N1  :  Regional  lymph  node  metastasis 
DISTANT  METASTASIS  (M) 
MX  :  Distant  metastasis  cannot  be  assessed 
M0  :  No  distant  metastasis 
M1  :  Distant  metastasis  
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STAGE  GROUPING 
Stage  I          T1   N0   M0 
Stage  II        T2   N0   M0 
Stage  IIIA   T3   N0   M0 
Stage  IIIB   T4   N0   M0 
Stage  IIIC  Any T    N1   M0 
Stage  IV    Any T  AnyN   M1. 
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ROLE  OF  IMMUNOHISTOCHEMISTRY  IN  DIFFERENTIATING  
PRIMARY  HEPATOCELLULAR,  CHOLANGIOCARCINOMA  AND  
METASTATIC  ADENOCARCINOMA  IN  COLORECTAL  REGION 
IHC  markers  are  used  to  study  HCC  and  to  differentiate  hepatocellular  
carcinoma  from  other  benign  and  malignant  mimics,  especially  intrahepatic  
cholangiocarcinoma  and  metastatic  adenocarcinoma.
[35,36]
 
Hurlimann  J  et  al    in  1991,  studied  that  C-reactive  protein  is  a  sensitive  
and  specific  marker for  HCC.  Factor  XIII  a,  can  also  be  used to  stain  
HCC.
[39]
 
In  2000,  T  Shimonishi
  
et  al  demonstrated  that  the  combined  immunostaining  
of  cytokeratins  7,  18,  19  and  20  is  useful  to  differentiate  intrahepatic  
cholangiocarcinomas  from  metastatic  adenocarcinomas  in  liver  and  from  
colorectal  and  gastric  regions.
[42]
 
Zhen  Fan,  M.D.  et  al  in  2003  studied  that  Hep  Par  1  as  a  useful  marker  
for  HCC.  It  is  not  100%  specific  because  it  stains  few  non hepatic  
malignancies.  Hence  Hep  Par  1  in  addition to  other  positive  and  negative  
markers  of  HCC  is  recommended  for  the  differential  diagnosis  of  HCC.
[41] 
In 2004,  Varma  and  Cohen  et  al  mentioned  that  among  the  many  diagnostic  
markers  studied,  pCEA,  HepPar  1,  CD34,  CK  7,  CK  19,  and  CK  20  have  
been  found  to  be  valuable  in  distinguishing  HCC  from  metastatic  neoplasms  
of  extrahepatic  sites.
[36] 
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Goodman  ZD  et  al  studied  in  2007,  that  as  the  neoplastic  cells  of  
hepatocellular  carcinoma  mimics  the  normal  liver  cells  both  by  functional 
and  morphological  characters.  Hence  it is difficult to differentiate  using  
immunostains,  even  though  if  present  they  are  not  100%  specific.
[37] 
In  2009,  Ali  Sawan  et  al  studied  that  CK7  and  CA19-9  positive  staining  
can  exclude  a  diagnosis  of  hepatocellular  carcinoma,  but  cannot  discriminate  
between  metastatic  carcinoma  (from    stomach  and  pancreaticobiliary  origin)  
and  cholangiocarcinoma.  The  CK20+/CK7–ve  phenotype  indicates  metastatic  
intestinal  adenocarcinoma,  most  often  from  the  colon  or  rectum.
[40]
 
  In 2012,  Daniela Fanni et al  revealed  in  his  study  that  there  are  no  stains  
that  can  absolutely  distinguish  well-differentiated  hepatocellular  carcinoma  
from  hepatic  benign  lesions,  Even  then,  selective  IHC  markers  can  be  used 
in addition  to  other  histopathological  features  and  can establish  the  diagnosis  
of  hepatocellular  carcinoma.
[38]
 
 Dana  T.Timek  et  al  in  2012  demonstrated  that  Arg-1  has  a  similar  
sensitivity  and  higher  specificity  in  differentiating  a  non-HCC  from  HCC  
when  compared  with  HepPar-1  and  glypican-3.  These  3  markers  are  
recommended  as  the  most  effective  panel  for  small  tissue  biopsy  or  FNA  
specimens  in  the  distinction  of  HCC  from  metastatic  carcinoma.
[43]
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TISSUE  MICRO  ARRAY 
 
The  tissue  microarray  (TMA)  technique  has  been  in  use  for  15  years.  The  
origin  of  TMAs  can  be  attributed  to  Dr  Hector  Battifora’s  humble  ‘sausage’  
blocks  (Figure 3),  in  which  a  number  of  tissues,  from  different  organs,  
were  put  together  in  the  same  block  and  the  reactivity  of  antigen/protein  
was  studied.  The  disadvantage  of  this  technique  was  when  tumors  or  tissues  
from  the  same  organ  were  put  together  it  was  difficult  and  impossible  to  
identify  them  back.
[44]
 
 The  technology  was  first  described  in  1987,  but  its  was  used  11  years  
later,  when  Kononen  and  colleagues  further  modified  and    developed  a  
device  that  could  rapidly  and  reproducibly  produce  TMAs  (Kononen  et  al.,  
1998).
[46] 
There  are  expensive  commercially  available  instruments( Beecher )  for  
making  microarray  blocks,  which  can  used  to  array  upto  1,000  cores  in  the  
same  block.   
The  next  step  in  the  development  of  TMA  was  described  by  Wan  et  al.  
who  used  a  16-gauge  needle  to  manually  bore  cores  from  tissue  blocks  and  
array  them  in  a  multi-tissue  straw  in  a  recognizable  pattern.  
[45] 
 
xli 
 
          
 
Fig  3  Demonstration  of  Battifora’s  Sausage  blocks 
 
Suk  Jin  Choi  et  al  concluded  that  simple  and  inexpensive  construction  of  
high-density  and  high-quality  TMAs  can  be  made  by  using  paraffinized  
agarose    gels  as  recipient  blocks.
[47]
                                       
APPLICATIONS 
TMA  shifts  the  research  from  basic  to  clinical  and  enables  researchers  to 
look  for  expression  of  specific  protein  on  tissue  samples  from  a  large  
cohort  of  patients  by  immunohistochemistry. 
All  researches  currently  done  in  conventional  histological  sections  from  
formalin  fixed  paraffin  embedded  tissue  are  possible  using  TMA.   
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Types  of  TMAs 
These  are  the  commonly  used  types  of  TMAs  used  depending  upon  the  
need  in  the  study  design. 
1.  Cell  line  arrays:  Used  to  detect  the  specificity  of  an  antibody  in  
finding  the  proteins.   
2.  Random  tissue/tumor  arrays:  Used  for  surveillance  of  antibodies  
which  were  already  in  use.  
 
3.  Consecutive  case  array:  Used  to  build  TMA  array  from  specific  
tissue  of  interest. 
4.   Tumor  characteristic-based  array:  A  special  type  of  array  used  to  
evaluate  a  single  parameter  of  a  tumour  such  as  patient  age  or  tumor  
grade. 
5.  Progression  arrays:  These  types  of  arrays  are  used  to  analyze  the  
role  of  protein(s)  in  cancer  progression.   
6.  Outcome  based  arrays [50,51] 
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Tissue  microarray  technique   
Microarray  is  a  technique  of  organizing  minute  amounts  of  tissues  of  
interest  on  a  solid  support.
[52]
  Tissue  microarrays  are  composite  paraffin  
blocks  constructed  by  extracting  cylindrical  tissue  core  “biopsies”  from  
different  paraffin  donor  blocks  and  re-embedding  these  into  a  single  
recipient  (microarray)  block  at  defined  array  coordinates. 
At  first,  the  donor  blocks  (invariably  stored  paraffin  blocks)  are  retrieved  
and  sectioned  to  produce  standard  microscopic  slides  that  are  stained  with  
hematoxylin  and  eosin.  Routinely  examines  the  slides  to  mark  the  area  of  
interest,  which  is  commonly  an  area  of  cancer  depending  upon  the  study  
design,  after  which  the  samples  can  be  taken  from  the  area  of  interest  and  
arrayed.
[53]
 
A  tissue  microarray  instrument  is  used  to  acquire  a  tissue  core  from  the  
donor  block.  This  core  is  then  placed  in  the  empty  cores,  which  are  
already  made  in  an  empty  paraffin  block—the  recipient  block.  The  core  is  
placed  at  a  specifically  assigned  coordinate  (X-Y  guide),  which  is  accurately  
recorded,  typically  on  a  spreadsheet.  Using  a  microtome,  the  sections  are  
cut  at  5  μm  from  the  tissue  microarray  blocks  to  generate  tissue  microarray  
slides  for  molecular  and  immunohistochemical  analyses. 
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Manual  Construction  of  a  TMA   
 
Fig  4  Diagrammatic  representation  of  construction  of  Manual  TMA   
Donor  block:  The  block  from  which  a  core  of  tissue  considered  for  study,   
is  called  as  the  donor  block.  This  is  done  by  examining  the  H  &  E  stained  
slides.  The  donor  blocks  should   not  contain  poorly  processed  areas.  Donor 
blocks  have  variable  depths  of  residual tissue.  These  lengths  depend  upon  
the  thickness  of  the  original  tissue when submitted for embedding, as well  as  
the number  of  sections  obtained   from  a  block  before  TMA construction. The 
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tissue within the block  should  be  at  least  1 mm  thick  to  allow  for  adequate  
core  length.  Preferably,  3  to  4 mm  of  tissue  thickness  is  recommended.     
Recipient  block:  The  empty  paraffin  block  in  which  the  cores  are  placed  is  
called  as  the  recipient  block.  The  cores  should  be  placed  towards  the  center  
of  this  block  in  order  to  prevent  cracking  of  the  block  leaving  around  3mm  
space  from  the  margins.  Multiple  sections  from  the  block  for  H  &  E,  and  
Special  studies  should  be  cut  at  the  same  time  to  prevent  wastage  of  tissue.  
========While creating the recipient holes within the microarray block, residual 
paraffin remains within the hole. As the donor cores are inserted into the recipient 
block, the residual paraffin is pushed into the hole. If the depth of the hole is 
insufficient, the compacted paraffin prevents proper insertion of the core with 
excessive tissue extrusion. This results in unnecessary tissue loss during block 
facing. Sufficiently deep holes allow space for residual paraffin to be compacted 
within the recipient block and prevent needless loss of the donor cores. Although 
excessive extrusion of cores results in unnecessary loss of tissue, it is just as 
important to avoid insertion of the cores below the surface of the  recipient block. 
Tissue length is inherently variable within the various cores. The length of tissue 
depends upon the thickness of tissue submitted for embedding, as well as the 
number of sections previously cut from the donor block. Therefore, many 
specimen cores will not span the entire depth of the TMA block. By inserting the 
cores below the surface of the block, multiple sections must be cut to face the 
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block and ensure all tissue discs are represented. Depending upon how deeply the 
cores were inserted, significant amount of tissue can be lost while attempting to 
ensure complete representation of all cores. Therefore, it is advisable to leave the 
cores slightly protruding from the recipient paraffin  block. 
The slight core protrusions can be corrected after completion of all core insertions. 
Space remains between the inserted cores and the recipient holes. Miniscule cracks 
form within the tissue cores and the recipient block during their various 
manipulations. These air pockets and cracks disrupt tissue discs during sectioning. 
By heating the TMA after core insertion, the cores are merged with the 
surrounding paraffi n, reducing the cracks and air  pockets. Ideally, complete 
melting of the paraffin allows appropriate merging of the cores with the recipient 
block. Unfortunately, completely melted paraffin does not support cores within the 
recipient block, which quickly lose their orientation in the heated liquid paraffi n. 
Therefore, moderate heating to soften, but not melt, the TMA block is used to 
slowly merge the cores with the paraffin. Delicate pressure applied to the surface 
of the heated recipient block aids in the merging. This can be accomplished by 
applying gentle pressure with a glass slide to the surface of the block. This step 
evenly completes the insertion of the cores. Multiple cycles of heating and cooling 
are used to adequately merge the block with the tissue cores and complete the 
creation of a TMA block.------------- 
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Size  of  the  cores:  TMA  tissue  discs  contain  a  limited  area  of  tissue. When 
selecting  the  area to  core,  focus  should  be  directed  toward  identifying  areas 
within  the  block   that fulfill  the  study  parameters  and  fit  within  the  area  of 
the  recipient  core  position. Another  consideration  is  the  location  of  cells 
within  tissue  discs. Cells  located  on  the  periphery  of  the  tissue  disc  are 
more  susceptible  to  artifacts,  such  as  nonspecific  immunohistochemical 
staining  of  tissue  edges,  and  can  seriously  confound  the  interpretation  of  the 
TMA  study. Ideally,  the  cells of interest  are  located  centrally  within  the  
tissue  cores.  Stylets  for  procurement  of  various  core  sizes  are  available, 
although  some  options  are  instrument  dependent.  For  most  instruments  and 
protocols,  diameter  options  range  between 0.6  and  2 mm. Beecher  Instruments 
offers  a  3-mm- diameter  core  needle  for  its  automated  arrayer  (ATA-27).  In 
general,  smaller  core  diameters  result  in  greater specimen number in each 
array block, resulting in higher throughput.  
The larger core diameters result in more tissue represented per specimen but fewer 
cases analyzed per slide. The decision of which diameter to use depends upon 
core-related artifact considerations, specimen number, and availability of donor 
tissue. During sectioning of the array, individual cores can fold, completely 
disrupting the tissue disc. The larger core sizes result in greater tissue disc area per 
section. Therefore, folding or disruption of larger cores more often results in 
partial obstruction of the individual sample. However, there is usually sufficient 
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intact  tissue  remaining to provide adequate analysis. With the larger core 
diameters, usually two cores are suffi cient to provide acceptable concordance 
rates. This reflects the greater tissue area available with the larger cores and their 
decreased likelihood of complete loss during sectioning artifact. On the other 
hand, the larger cores cause greater disruption of donor blocks. The larger needles 
are relatively more likely to crack and fragment the tissue block when punching 
cores. The fragmentation or disruption of the original block destroys its use for 
further studies. This is problematic if the tissue block is needed for further 
diagnostic or research purposes. In comparison, the smaller cores cause less 
disruption of the donor block and less artifact when the donor block is sectioned 
after core removal. Therefore, if the integrity of the original donor block is 
imperative, smaller core sizes should be considered.  
Density:  The  maximum  number  of  cores  that  can  be  placed  on  a  single  
block  is  variable,  depending  on  size  of  the  core  and  block.  Cores  should  
start  at  least  3  mm  away  from  the  block  edges,  to  prevent  the  paraffin  
from  cracking.   
Distance:  Placement  of  many  cores  close  to  one  another  distorts  the TMA. 
Cores located within  the  center  of  the  block  will  be   higher  than  the  cores  
in  the  periphery,  making  it  difficult  to  face  the  block  without  losing 
significant  amount  of  tissue.   Therefore,  the  cores  within  the  recipient  block  
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should  be  adequately  spaced.  Most  protocols  recommend  a  spacing  of  0.7  
to  0.8 mm  between  core.       
ADVANTAGES 
 Amplification  of  a  scarce  resource 
 Simultaneous  analysis  of  very  large  numbers  of  specimens. 
 Uniformity 
 Decreased  assay  volume,  time  and  cost. 
 Original  block  was  not  destroyed  for  diagnosis  and  thus  conserves  
valuable  tissue. 
 Effective  for  assessing  quality  control  assurance  programs  such  as  
intra-  and  interlaboratory  variation  in  immuno-histochemical  and  molecular  
studies  and  as  a  efficient  tool.
[54,55,56]
 
 
LIMITATIONS 
 In  case  of  heterogenous  tumours,  multiple  cores  must  be  taken  in  
order  to  avoid  false  negative  results. 
 Requires  experienced  personnel  and  expensive  equipment. 
 High  cost.[57] 
Commercial  TMA  arrayer  machines  such  as  automated  and  semiautomatic  
tissue  arrayers  are  expensive.  A  relatively  simple  and  inexpensive  alternative  
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is  the  use  of  lab-made  recipient  paraffin  blocks  and  ordinary  cannula-
piercing  needles,  skin  biopsy  punches,  and  bone  marrow  biopsy  needles.
[58]
   
  Chang  Hwan  Choi  concluded  that  by  using  cannula  piercing  needles  and  
recipient  paraffin  blocks,    high  density  TMAs  with  varying  core  diameters  
(0.6  mm,  1  mm,  2  mm,  3  mm,  and  5  mm)  can  be  constructed  at  low  cost.  
The  arrays  were  fairly  well  established  in  terms  of  alignment  of  the  tissue  
cores,  so  that  we  were  able  to  appreciate  the  histologic  and  
immunohistochemical  features  of  the  TMA  sections  without  substantial  
difficulty. 
By  using  TMA  kits  made  from  bone  marrow  biopsy  needles,  disposable  
skin  biopsy  punches  and  metallic  ink  cartridges  of  ballpoint  pens,  
researchers  are  able  to  construct  low  cost  TMAs.
[58]                                       
 
MECHANICAL  PENCIL  TIP  NEEDLE  METHOD(Figure No. 5,6) 
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Fig  5  &  6  Demonstration  of  Mechanical  pencil  tip  technique 
 
Abdelhadi  M  Shebl  et  al  concluded  that    mechanical  pencil  tip  technique  is  
the  most  inexpensive  easy  technique  among  the  literature.  It  also  takes  a  
reasonable  amount  of  time  and  reduces  antibody  consumption.  The  major  
disadvantage  of  TMA  technology  is  the  cost,  hence  these  inexpensive  will  
improve  the  basic  research(Figure  5  &  6). 
[59] 
Mohamed  a  Elkablawy  stated  that    conventional  TV/radio  telescopic  antenna  
can  be  used  to  punch  tissue  cores  manually  from  donor  paraffin  embedded  
tissue  blocks  which  were  pre-incubated  at  40
o
C.  The  technique  was  simple  
and  caused  minimal  damage  to  the  donor  blocks.   He  concluded  that  this  
technique  is  easy  to  reproduce,  quick,  inexpensive  and  creates  uniform  
blocks  with  abundant  tissues  without  specialized  equipment.  It  was  found  to  
improve  the  stability  of  the  cores  within  the  paraffin  block  and  facilitated  
no  losses  during  cutting  and  immunostaining.
[60]
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Fig  7  Usage  of  conventional  TV  Antenna  in  construction  of  TMA 
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Immunohistochemistry: 
Immunohistochemistry  involves  two  disciplines  –  immunology  and  histology. 
Immunohistochemistry  is  used  to  determine  expression  of  particular  antigen  
and  its  microanatomic  location  in  the  tissue.  IHC  uses  antibodies  to  
distinguish  antigenic  differences  between  the  cells.  These  differences  can  
specifically  identify  the  lineage  of  cell  populations  and  define  biologically  
distinct  population  of  cells  within  the  same  lineage. 
                                       Antigen  retrieval  technique  was  introduced  by  Shi  
and  associates  in  1991.  It’s  a  simple  method  that  involves  heating  paraffin  
sections  to  a  high  temperature  before  IHC  staining.The  use  of  antiboby  in  
IHC  depends  on  sensitivity  and  specificity  of  antigen  antibody  reaction  and  
the  hybridoma  technique  provides  limitless  source  of  highly  specific  
antibodies. 
Detection  systems  : 
                                  Antibodies  are  labeled  or  flagged  by  some  method  to  
permit  visualization  –  these  include  fluorescent  substances  ,  enzymes  
forming  coloured  reaction  with  suitable  substrate  (  light  microscopy  )  or  
heavy  metals  (  electron  microscopy  ). 
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Methods  of  IHC  : 
Direct  conjugate  labeled  antibody  method  : 
                                                                           Antibody  is  attached  with  a  label  
by  chemical  means  and  directly  applied  to  tissue  sections.  It  is  a  rapid  and  
easy  procedure  and  involves  detection  of  multiple  antigens  which  require  
separate  incubation  with  specific  antibodies. 
Indirect  sandwich  method  : 
                                                     Enzymes  are  labeled  with  secondary  antibody  
which  is  produced  against  primary  antibody.  The  advantages  are  increased  
versatality  ,  high  working  dilution  of  primary  antibody  and  easy  preparation  
of  secondary  antibodies  against  a  primary  antibody  of  different  species. 
Unlabelled  antibody  methods  : 
Enzyme  bridge  technique  : 
                                                Here  the  labeled  moiety  is  linked  to  the  antigen  
solely  by  immunologic  binding. 
Peroxidase  antiperoxidase  method  : 
                                                          The  principle  of  the  PAP  method  is  
similar  to  that  of  the  enzyme  bridge  method.  The  acronym  PAP  denotes  the  
peroxidase  antiperoxidase  reagent  that  consists  of  antibody  against  
horseradish  peroxidase  and  horseradish  peroxidase  antigen  in  the  form  of  a  
small,  stable  immune  complex.  Available  evidence  suggests  that  this  
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immune  complex  typically  consists  of  two  antibody  molecules  and  three  
horseradish  peroxidase  molecules  in  the  configuration.  The  PAP  reagent  and  
the  primary  antibody  must  be  from  the  same  species  (or  from  closely  
related  species  with  common  antigenic  determinants),whereas  the  bridge  or  
linking  antibody  is  derived  from  a  second  species  and  has  specificity  
against  the  primary  antibody. 
Avidin  biotin  technique  : 
                                                    The  high  affinity  between  biotin  and  avidin  is  
used  in  this  technique  ;.  Biotin  binds  to  the  primary  antibody  and  avidin  
binds  to  the  enzyme  thus  attaching  it  to  the  biotinylated  antibody.  
Disadvantage  of  this  procedure  is  the  presence  of  endogeneous  biotin  
activity  that  produces  non  specific  background  staining. 
Avidin  biotin  conjugate  procedure  : 
                                      Here  the  primary  antibody  is  added  followed  by  
biotinylated  secondary  antibody  and  next  preformed  complexes  of  avidin  and  
biotin  horse  radish  peroxidase  conjugate. 
Biotin  streptavidin  system  : 
                                                            Streptavidin  is  used  in  place  of  avidin,  
Streptavidin  complexes  are  more  stable  compared  to  avidin. 
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Immunogold  silver  technique  : 
                                                  This  is  used  in  ultrastructural  
immunolocalisation.  Gold  particles  are  enhanced  by  addition  of  several  
layers  of  silver. 
Polymeric  method  : 
                                    This  technique  allows  the  binding  of  a  large  number  of  
enzyme  molecules  to  a  secondary  antibody  via  dextran  backbone.  The  
advantages  of  this  technique  are  increased  sensitivity  ,  minimized  non  
specific  background  staining  and  reduction  in  number  of  assay  steps. 
Alkaline  phosphatase  and  anti  alkaline  phosphatase  method  : 
                                                      The  principle  is  the  same  as  that  of  PAP  
method  .   
Tissue  fixation  ,  Processing  and  antigen  retrieval  techniques  : 
                                                                                                                  Tissues  for  
IHC  undergo  fixation  ,  dehydration  and  Paraffin  embedding. 
Fixation  : 
                                    This  is  a  critical  step  as  preservation  of  morphology  is  
essential  for  interpretation  .  10  %  neutral  buffered  formalin  is  used  .It  has  
the  following  advantages  : 
1.  Good  morphological  preservation 
2.  Cheap  ,  easily  available  ,  penetrates  tissues  well  and  sterilizes  them. 
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3.  Carbohydrate  antigens  are  better  preserved  and  does  not  interfere  with  
the  staining  process. 
The  disadvantage  of  masking  antigens  during  fixation  can  be  overcome  by  
antigen  retrieval  technique  . 
Antigen  retrieval: 
                  The  following  techniques  are  used  for  unmasking  of  the  antigen  : 
1. Proteolytic  enzyme  digestion 
2. Microwave  antigen  retrieval   
3. Microwave  and  trypsin  antigen  retrieval  technique 
4. Pressure  cooker  antigen  retrieval. 
 
IHC MARKERS 
Hep Par-1  (Hepatocyte  Paraffin  1)  is  a  monoclonal  antibody  that  reacts  
with  an  epitope  of  liver  mitochondria,  with  a  typical  granular  pattern  in  
most  liver  specimens.    It  also    reacts  with  other  normal  or  pathological  
structure,  such  as  renal  tubules  and  intestinal  epithelium  as  well  as  with  
intestinal  metaplasia  in  the  stomach  and  esophagus
[37]
.  It  produces  positive  
staining  in  the    majority  of  cases  of  hepatocellular  carcinoma  and  only  a  
small  percentage  of  other  tumors,  including  some  cholangiocarcinomas  and  
metastatic  adenocarcinomas  from  the  stomach  and  other  sites
[64]
. Few  
scientific  literatures  reported  cases  of  hepatocellular  carcinoma  negative  for  
lviii 
 
Hep Par-1,  probably  due  to  the  uneven  distribution  of  Hep Par-1  in  
hepatocellular  carcinoma.
[62,63] 
The  expression  of  the  marker  decreases with  
decreasing  differentiation  of  the  tumour.   
The  commercially  available  Hep  Par  1antibody  (clone  OCH1E5.2.10)  stains  
normal  and neoplastic  hepatocytes.  This  antibody  was  developed  in  1993  by  
Wennerberg  et  al.
[65]
    using  fixed  liver  as  immunogen.  The  target  antigen  
has  not  yet  been  fully  determined.  
 
Cytokeratins  (CKs)  represent  the  epithelial  class  of  intermediate-  sized  
filaments  of  the  cytoskeleton.  There  are  20  subtypes  of  cytokeratin  (CK)  
intermediate  filaments.  These  have  different  molecular  weights  and  
demonstrate  differential  expression  in  various  cell  types  and  tumors.  Among  
the  most  useful  cytokeratins  are  CK7  and  CK20.  CK7  is  found  in  many  
ductal  and  glandular  epithelia,  including  lung,  breast,  ovary,  and  
endometrium.  CK20  is  expressed  in  the  gastrointestinal  (GI)  epithelium,  
urothelium,  and  Merkel  cells.  The  combined  expression  patterns  of  CK7  and  
CK20  have  been  extensively  studied  in  various  primary  and  metastatic  
carcinomas.  CK20  is  expressed  alone  in  the  majority  of  intestinal  
adenocarcinoma  and  in  Merkel  cell  carcinomas  whereas  CK7  is  present  
without  CK20  in  most  breast,  lung  and  ovarian  adenocarcinoma,  and  with  
CK20  in  urothelial,  pancreatic  and  gastric  carcinomas.  The  CK7-/CK20+  
expression  pattern  is  known  to  be  highly  characteristic  of  colorectal  
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carcinomas,  however,  not  all  colorectal  carcinomas  show  the  CK7-/CK20+  
expression  pattern.  Occasionally  colorectal  carcinomas  may  show  significant  
CK7  expression  and  conversely,  expression  of  CK20  may  be  seen  in  a  
variety  of  non-colorectal  adenocarcinomas  such  as  urothelial,  gastric  and  
pancreatobiliary  tract  carcinomas.
[66] 
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MATERIALS  AND  METHODS 
The  study  was  carried  out  in  the  Department  of  Pathology,  Govt.  Stanley  
Medical  College,  from  July  2012  to  June  2015  after  obtaining  the  approval  
from  Institutional  Human  Ethical  Committee  (IHEC)  of  Govt.  Stanley  
Medical  College,  Chennai. 
Total  of  60  specimens  were  taken  for  this  study. 
INCLUSION  CRITERIA 
Histologically  diagnosed  cases  of  primary  hepatocellular  carcinoma,  
cholangiocarcinoma  and  metastatic  secondaries  from  colorectal  region  in  
liver.  (Trucut  biopsies  and  resection  specimens). 
EXCLUSION  CRITERIA 
Benign  tumours  of  liver,  tumours  of  liver  in  infancy,  mesenchymal  tumours  
of  liver. 
METHODOLOGY 
For  all  the  60  cases,  details  of  age,  sex  and  other  relevant  clinical  data  
were  recorded. 
Microscopically  diagnosed  cases  of  primary  hepatocellular  carcinoma(well  
differentiated,  moderately  differentiated  and  poorly  differentiated  ),  intra 
hepatic  cholangiocarcinoma  and  metastatic  secondary  deposits  in  liver  from  
colorectal  region  in  liver  biopsies  specimens  were  selected  randomly  
irrespective  of  age  and  sex. 
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      Method  of  data  collection  : 
                                                          All  Liver  Biopsies  and  Resection  
specimens  received  in  the  Department  of  Pathology,  Govt.  Stanley  Medical  
College  were  included  in  the  study.  10%  Neutral  buffered  formalin  was  
used  as  fixative.    Appropriate  tissues  were  sampled  and  the  tissues  were  
processed  in  various  grades  of  alcohol  and  xylol  using  automated  
histokinette.  Paraffin  blocks  were  prepared  and  sections  of  5  micron  
thickness  were  cut  and  stained  using  H&  E  technique  and  examined  under  
the  microscope  for  histopathological  diagnosis  and  were  taken  up  for  the  
study(Using  inclusion  and  Exclusion  criteria).  All  the  selected  cases  were  
included  in  the  construction  of  tissue  microarray. 
Construction  of  Tissue  Microarray 
H  &  E  slides  were  screened  and  the  areas  of  interest  were  marked  with  
marker  pen  which  were  again  marked  in  the  donor  block.  The  recipient  
blocks  were  made  by  coring  the  paraffin  block  using  14  gauge  bone  
marrow  aspiration  needles  and  the  arrangement  of  the  cores  should  be  
asymmetrical. 
The  cores  from  the  donor  block  were  taken  from  the  areas  of  interest  using  
16  gauge  needle.  The  diameter  of  the  core  was  1mm.  These  cores  were  
placed  in  the  recipient  blocks  as  per  our  TMA  design.  This  was  placed  in  
incubator  at  37
o
C  for  24  hrs  and  kept  in  freezer  compartment  of  
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refrigerator  before  sectioning.  Each  recipient  block  contains  both  controls  
and  test  tissue  cores.  The  controls  for  Hep  par1,  CK7,19,20  are  normal  
liver  tissue,  moderately  differentiated  gastric  carcinoma,  cholangiocarcinoma  
and  moderately  differentiated  colonic  adenocarcinoma  respectively. 
Sections  were  taken  for  IHC  at  4  micron  thickness  in  chrome  alum  coated  
slides  using  semi-automated  microtome  with  disposable  blades.  The  slides  
were  kept  in  incubator  at  70
o
C  for  an  hour.   
Only  60  cases  were  studied  in  this  study  in  view  of  less  availability  of  
carcinomas  of  liver  in  2012-  2014.   
Sections  were  subjected  to  antigen  retrieval  technique  by  pressure  cooker  
method  using  TRIS  EDTA  (  Ph  9)  buffer  solution  and  then  treated  by  HRP  
(  horse  radish  peroxidase  )  polymer  technique. 
HRP  polymer  Technique  :     
1. The  sections  were  deparaffinised  in  xylene  or  xylene  substitutes 
2. Rehydrated  through  graded  alcohols 
3. The  slides  were  then  washed  in  running  tap  water 
4. The  antigen  retrieval  was  performed  using  the  appropriate  buffer(TRIS  
EDTA)  by  pressure  cooker  method. 
5. The  endogeneous  peroxide  was  blocked  using  peroxidase  block  for  5  
mins   
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6. Slides  were  then  washed  in  2  changes  of  TBS  buffer  for  5  mins  
each. 
7. Primary  antibody  was  then  used  to  incubate  the  slides  for  60  mins. 
8. Then  the  slides  were  washed  in  2  changes  of  TBS  buffer  for  5  mins  
each. 
9. Then  incubation  was  done  with  target  binder  for  15  mins   
10.   Then  the  slides  were  washed  in  2  changes  of  TBS  buffer  for  5  
mins  each. 
11.   Then  incubation  with  HRP  labeled  polymer  for  15  mins 
12.   Then  the  slides  were  washed  in  2  changes  of  TBS  buffer  for  5  
mins  each. 
13.   Then  incubated  with  3-3’diamino  benzidine(DAB)  substrate             
chromogen  working  solution  which  results  in  brown  colored  staining. 
14.   The  slides    were  then  rinsed  in  water,  counterstained  in  hematoxylin  
,  washed  in  water,  dehydrated  ,  cleared  and  mounted  to  be  examined. 
EVALUATION  OF  IMMUNOSTAINING 
Hep  Par  1  –  In  this  study  we  have  used  mouse  monoclonal  antibody  
which  shows  granular  cytoplasmic  positivity  in  immunostaining.  The  staining  
was  observed  in  normal  and  neoplastic  hepatocytes.  The  intensity  of  
staining  was  scored
[2]
  as- 
0  =  no  reactivity; 
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  1  =  less  than  5%  of  cancer  cells  positive; 
  2  =  5  -  25%  positive; 
  3  =  25  -  50%  positive, 
4  =  50  -  75%  positive;   
5  =  75  -  90%  positive;  and 
6  >  90%  of  tumour  cells  positive. 
CK  7,  19,  20  -  In  this  study  we  have  used  rabbit  monoclonal  antibodies  
which  shows  brown  cytoplasmic  and  membranous  staining.  Positive  
immunoreactivity  was  defined  as  more  than  20%  of  cells  staining  with  the  
proper  pattern  of  reactivity
[40]
. 
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OBSERVATION  AND  RESULTS 
 
In  this  present  study  we  have  included  60  cases  of  liver  biopsies  and  
resection  specimens,  out  of  which  30  were  hepatocellular  carcinoma,  14  
were  cholangiocarcinoma  and  16  were  metastatic  adenocarcinomatous  deposit  
in  liver  from  colorectal  region  fulfilling  the  inclusion  and  exclusion  criteria.
 
GRAPH  NO.1-  TOTAL  NO.  OF  CASES 
 
In  this  study(Graph  no.1)  50%  samples  were  cases  of  Hepatocellular  
carcinoma,  23%  were  Intrahepatic  cholangiocarcinoma  and  27%  were  
metastatic  adenocarcinomatous  deposit  in  liver  from  colorectal  region.   
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GRAPH  NO.2-  YEAR  WISE  DISTRIBUTION  OF  CASES 
Out  of  the   60  samples  studied,  as  depicted  in  the  graph  above(Graph  no.  
2),  the  samples  of  hepatocellular  carcinoma  was  high  compared  to  
Intrahepatic  cholangiocarcinoma  and  Metastatic  adenocarcinomatous  deposit  
in  liver  from  colorectal  region  in  2012  and  2013.  In  2014,  the  samples  of  
Hepatocellular  carcinoma  and  Intrahepatic  cholangiocarcinoma  were  equal.  In  
2015,  only  2  samples  were  studied  which  were  Intrahepatic  
cholangiocarcinoma  and  Metastatic  adenocarcinomatous  deposit  in  liver  from  
colorectal  region. 
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GRAPH  NO.  3-  AGE  WISE  DISTRIBUTION  OF  CASES 
 
Out  of  the  60  samples  studied (Graph  no.  3),  majority  of  cases  with  
Hepatocellular  carcinoma,  Cholangiocarcinoma  and  Metastatic  
Adenocarcinomatous  deposit  in  liver  were  between  51  to  70  years  and  a  
few  less  than  30  years.  The  study  had  a  range  of  age  group  from  27  to  
80years.  Between  31  to  50  years,  the  incidence  of  hepatocellular  carcinoma  
was  high  compared  the  other  two  neoplasms  in  liver.  More  than  70  years,  
the  incidence  of  Metastatic  Adenocarcinomatous  deposit  in  liver  was  high  
compared  to  other  neoplasms  in  liver.  While  there  is  only  one  case  of  
Hepatocellular  carcinoma  below  30  years.   
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Age  
Distribution 
Hepatocellular  
Carcinoma 
% Hilar  
Cholangio  
Carcinoma 
% Metastatic  
Adenocarcinomatous  
Deposit 
% 
≤  30  years 1 3.33 0 0.00 0 0.00 
31-50  years 13 43.33 3 21.43 2 12.50 
51-70  years 15 50.00 9 64.29 9 56.25 
>  70  years 1 3.33 2 14.29 5 31.25 
Total 30 100 14 100 16 100 
 
TABLE  NO.  1-  AGE  WISE  DISTRIBUTION  OF  CASES 
 
Age  Distribution Hepatocellular  Carcinoma Hilar  Cholangio  
Carcinoma 
Metastatic  
Adenocarcinomatous  
Deposit 
N 30 14 16 
Mean 51.63 57.43 63.19 
SD 10.85 12.16 14.26 
 
TABLE  NO.  2  COMPARISON    OF    MEAN    AGE    BETWEEN    THE    
THREE  STUDY  GROUPS 
The  above  table (Table  no.2)  depicts  the  mean  age  incidence  of  
Hepatocellular  carcinoma  as  51.63  years,  Cholangiocarcinoma  as  57.43  years  
and  Metastatic  Adenocarcinomatous  deposit  in  liver  as  63.19  years. 
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GRAPH    NO.  4  GENDER    DISTRIBUTION    OF    CASES   
The  incidence  of  Hepatocellular  carcinoma,  Cholangiocarcinoma  and  
Metastatic  Adenocarcinomatous  deposit  in  liver  was  common  in  males  
compared  to  that  of  females.  The  incidence  of  Hepatocellular  carcinoma  
was  high  in  both  gender  compared  to  the  other  two  malignancies.(Graph  
no.4  and  Table  no.3). 
Gender  
Distribution 
Hepatocellular  
Carcinoma 
% Hilar  
Cholangio  
Carcinoma 
% Metastatic  
Adenocarcinomatous  
Deposit 
% 
Male 18 60.00 12 85.71 10 62.50 
Female 12 40.00 2 14.29 6 37.50 
Total 30 100 14 100 16 100 
 
TABLE  NO.3-  GENDER  DISTRIBUTION  OF  CASES 
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GRAPH  NO.  5  –  DISTRIBUTION  OF  HEPATOCELLULAR  
CARCINOMA  ACCORDING  TO  DIFFERENTIATION 
In  this  study,  out  of  30  cases  of  hepatocellular  carcinoma,    11  were  well  
differentiated,  3  were  moderately  differentiated  and  16  were  poorly  
differentiated  hepatocellular  carcinomas.(Graph  No.  5) 
 
GRAPH  NO.6  DISTRIBUTION  OF  HEPATOCELLULAR  
CARCINOMA  ACCORDING  TO  Hep  Par  1  REACTIVITY  WITH  
RESPECT  TO  DIFFERENTIATION  OF  TUMOURS 
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The  above  graph(Graph  no.6)  depicts  the  scoring  of  Hep  par1  staining  in  
different  grades  of  Hepatocellular  carcinoma.  Out  of  30  cases,  6  cases  were  
negative  and  all  6  belongs  to  poorly  differentiated  hepatocellular  carcinoma.  
In  well  differentiated  group  out  of  11  cases,  6  were  showing  6+  positivity,  
4  were  showing  5+  positivity  and  1  case  showed  4+  positivity. In  
moderately  differentiated  group  out  of  3  cases,  1  case  was  6+  positivity,  1  
was  5 +  positivity  and  one  more  showed  3+  positivity. In  poorly  
differentiated  group,  6  cases  were  negative,  7  cases  showed  2+  positivity  
and  3  cases  showed  1+  positivity. 
 
 
GRAPH  NO.  7  DISTRIBUTION  OF  Hep  par1  REACTIVITY  IN  ALL  
THREE  MALIGNANCIES 
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In  this  study,  out  of  30  cases  of  Hepatocellular  carcinoma,  24  cases  were  
positive  for  Hep  par1  and  6  cases  were  negative  for  Hep  par1.  Hep  par1  
was  negative  for  100%  cases  of  Intrahepatic  Cholangiocarcinoma  and  
Metastatic  Adenocarcinomatous  Deposit  in  liver  from  colorectal  
region.(Graph  No.  7  &  Table  no.  4) 
Hep  Par1  
Positivity 
Hepatocellular  
Carcinoma 
% Hilar  
Cholangio  
Carcinoma 
% Metastatic  
Adenocarcinomatous  
Deposit 
% 
Hep  Par1  
Positive 
24 80 0 0.00 0 0.00 
Hep  Par1  
Negative 
6 20 14 100.00 16 100.00 
Total 30 100 14 100 16 100 
 
TABLE  NO.  4  -  DISTRIBUTION  OF  Hep  par1  REACTIVITY  IN  ALL  
THREE  MALIGNANCIES 
 
GRAPH  NO.  8  -  DISTRIBUTION  OF  CK  7  REACTIVITY  IN  ALL  
THREE  MALIGNANCIES 
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CK  7  
Positivity 
Hepatocellular  
Carcinoma 
% Hilar  
Cholangio  
Carcinoma 
% Metastatic  
Adenocarcinomatous  
Deposit 
% 
CK  7  
Positive 
1 3.33 14 100.00 1 6.25 
CK  7  
Negative 
29 96.67 0 0.00 15 93.75 
Total 30 100 14 100 16 100 
 
TABLE  NO.  5-  DISTRIBUTION  OF  CK  7  REACTIVITY  IN  ALL  
THREE  MALIGNANCIES. 
In  this  study,(Graph  no.  8  &  Table  No.  5)  CK  7  was  positive  in  100%  
cases  of  Cholangiocarcinoma,  3.33%  0f  Hepatocellular  carcinoma  and  6.25%  
in  Metastatic  Adenocarcinomatous  deposit  in  liver  from  colorectal  region.  
CK  7  was  negative  in  96.67%  cases  of  Hepatocellular  carcinoma  and  
93.75%  cases  of  Metastatic  Adenocarcinomatous  deposit  in  liver  from  
colorectal  region. 
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GRAPH  NO.  9  -  DISTRIBUTION  OF  CK  19  REACTIVITY  IN  ALL  
THREE  MALIGNANCIES 
CK  19  
Positivity 
Hepatocellular  
Carcinoma 
% Hilar  
Cholangio  
Carcinoma 
% Metastatic  
Adenocarcinomatous  
Deposit 
% 
CK  19  
Positive 
0 0.00 5 35.71 10 62.50 
CK  19  
Negative 
30 100.00 9 64.29 6 37.50 
Total 30 100 14 100 16 100 
 
TABLE  NO.  6  -  DISTRIBUTION  OF  CK  19  REACTIVITY  IN  ALL  
THREE  MALIGNANCIES 
In  this  study,  CK  19  was  positive  in  35.71%  cases  of  
Cholangiocarcinoma  and  62.50%  in  Metastatic  Adenocarcinomatous  deposit  
in  liver  from  colorectal  region.  CK  19  was  negative  in  100%  cases  in  
Hepatocellular  carcinoma,  64.29%  cases  in  Cholangiocarcinoma  and  
37.50%  in  Metastatic  Adenocarcinomatous  deposit  in  liver  from  colorectal  
region.(Graph  no.  9  &  Table  No.  6) 
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GRAPH  NO.  10-    DISTRIBUTION  OF  CK  20  REACTIVITY  IN  ALL  
THREE  MALIGNANCIES 
 
 
CK  20  
Positivity 
Hepatocellular  
Carcinoma 
% Hilar  
Cholangio  
Carcinoma 
% Metastatic  
Adenocarcinomatous  
Deposit 
% 
CK  20  
Positive 
0 0.00 0 0.00 14 87.50 
CK  20  
Negative 
30 100.00 14 100.00 2 12.50 
Total 30 100 14 100 16 100 
 
TABLE  NO.  7  -  DISTRIBUTION  OF  CK  20  REACTIVITY  IN  ALL  
THREE  MALIGNANCIES 
In  this  study,  CK  20  was  positive  only    in  87.50%  cases  of  Metastatic  
Adenocarcinomatous  deposit  in  liver  from  colorectal  region.  CK  20  was  
negative  in  100%  cases  of  Hepatocellular  carcinoma  and  
Cholangiocarcinoma  with  12.50%  cases  of  Metastatic  Adenocarcinomatous  
deposit  in  liver  from  colorectal  region.(Graph  no.  10  &  Table  No.  7) 
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DISCUSSION 
This  cross  sectional  study  was  carried  out  in  the  Department  of  Pathology,  
Govt.  Stanley  Medical  College.  Total  number  of  cases  studied  were  60,  
which  included  30  cases  of  Hepatocellular  carcinoma(11-well  
differentiated,3-moderately  differentiated,16-poorly  differentited),  14  cases  of  
Intrahepatic  cholangiocarcinoma  and  16  cases  of    Metastatic  
Adenocarcinomatous  deposit  in  liver  from  colorectal  region. 
1.AGE  OF  THE  PATIENT 
In  our  study  the  age  of  the  patient  with  Hepatocellular  carcinoma  ranges  
from  27  to  73  years  with  mean  age  of  51.3  years(Graph  No.3,Table  No.1  
&  2).   
In  2012,  Hashem  B.  El-Serag,  studied  the  epidemiology  of  HCC  world  
wide  and  concluded  that  in  low  risk  population  the  incidence  is    >70  years  
and  in  high  risk  groups  it  is  between  50  to  60  years
[68]
. 
In  2014  Subrat  K.  Acharya  studied  the  epidemiology  of  Hepatocellular  
carcinoma  in  India  and  concluded  that  the  age  ranges  between  40  to  70  
years  at  the  time  of  presentation.
[67] 
In  our  study  the  age  of  the  patient  with  Intrahepatic  cholangiocarcinoma  
ranges  from  35  to  80  years,  with  mean  age  of  57.43  years. 
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Ahmad  Ramzi  Yusoff  et  al.  studied  the  survival  analysis  of  
cholangiocarcinoma  and  revealed  that  the  mean  age  of  diagnosis  is  61  
years
[69]
. 
Sean  F.  Altekruse  studied  the  geographic  variation  of    Intrahepatic 
Cholangiocarcinoma,  Extrahepatic  Cholangiocarcinoma,  and  Hepatocellular 
Carcinoma  in  the  United  States  and  stated  that  incidence  was  high  in  all  
three  cancers  in  age  group  of  more  than  70  years
[70]
. 
In  our  study  the  age  of  the  patient  with  Metastatic  Adenocarcinomatous  
deposit  in  liver  from  colorectal  region  ranges  from  32  to  89  years  with  
mean  age  being  63.19  years.   
Sylvain  Manfredi  et  al  studied  the  epidemiology  of  liver  colorectal  cancer  
metastases    and  concluded  that  the  peak  incidence  of  metastasis  is  from  65  
and  74  years
[71]
. 
2.  GENDER   
In  our  study  in  all  the  three  malignancies  of  the  liver,  the  incidence  is  
high  in  males  compared  to  that  of  females.  60%  in  Hepatocellular  
carcinoma,  85.71%  in  Intrahepatic  cholangiocarcinoma  and  62.5%  in  
Metastatic  Adenocarcinomatous  deposit  in  liver  from  colorectal  region.   
In  2014  Subrat  K.  Acharya  studied  the  epidemiology  of  Hepatocellular  
carcinoma  in  India  and  concluded  that  the  male  to  female  ratio  is  4:1  in  
India
[67]
. 
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  In  2012,  Hashem  B.  El-Serag,  studied  the  epidemiology  of  HCC  world  
wide  and  concluded  that  men  are  at  increased  risk  for  HCC  partly  because  
they  have  a  greater  incidence  of  viral  hepatitis  and  alcoholic  cirrhosis.
[68] 
Sean  F.  Altekruse  studied  the  geographic  variation  of    Intrahepatic 
Cholangiocarcinoma,  Extrahepatic  Cholangiocarcinoma,  and  Hepatocellular 
Carcinoma  in  the  United  States  and  stated  that  the  male  to  female  ratio  is  
less  than  two-fold  for  ICC  (1.4  to  1)
[70]
. 
Sylvain  Manfredi  et  al  studied  the  Epidemiology  of  Liver  Colorectal  Cancer  
Metastases    and  concluded  that  the  sex  ratio  is  2:1
[71]
. 
3.Hep  Par1 
  Out  of  30  cases,  6  cases  were  negative  and  all  6  belongs  to  poorly  
differentiated  hepatocellular  carcinoma.  In  well  differentiated  group  out  of  
11  cases,  6  were  showing  6+  positivity(Figure 21),  4  were  showing  5+  
positivity(Figure 26)  and  1  case  showed  4+  positivity.  In  moderately  
differentiated  group  out  of  3  cases,  1  case  was  6+  positivity,  1  was  5+  
positivity  and  one  more  showed  3+  positivity.  In  poorly  differentiated  
group,  6  cases  were  negative,  7  cases  showed  2+  positivity  and  3  cases  
showed  1+  positivity. 
Razia  Hanif  evaluated  the  diagnostic  utility  of  Hep  par-1  in  differentiating  
hepatocellular  carcinoma  from  metastatic  carcinoma  and  concluded  that  The  
sensitivity  of  Hep  par-1  was  83.3%,  specificity  was  96.6%,  positive  and  
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negative  predictive  values  and  accuracy  were  96.5%,  85.2%  and  90%  
respectively. 
In  our  study  the  sensitivity  of  Hep  par1  was  80%,  specificity  was  100%,  
positive  and  negative  predictive  values  are  100%  and  72%  respectively
[2]
. 
Zhen  Fan  et  al  in  his  study  in  2002  named  Hep  Par  1  Antibody  Stain  for  
the  Differential  Diagnosis  of  Hepatocellular  Carcinoma:  676  tumors  tested  
using  tissue  microarrays  and  conventional  tissue  sections  revealed  that  out  
of  19  cases  of  HCC,  18  were  positive.  The  one  negative  case  was  a  poorly  
differentiated  HCC.  Hep  Par  1  staining  in  HCC  is  frequently  uneven  and  
patchy  compared  to  the  more  uniform  staining  of  adjacent  nonneoplastic  
liver
[71]
. 
Minervini  et  al.  and  Chu  et  al.  observed  that  poorly  differentiated  HCCs  
are  more  likely  to  be  negative  for  Hep  Par  1  than  better  differentiated  
cases.  This  findings  reveals  that  poorly  differentiated  HCCs  loses  its  
reactivity  for  Hep  par1.
[7,9]
 
Sugiki  et  al  in  2004  revealed  in  his  study  that  the  negativity  of  Hep  Par1  
in  few  cases  of  HCC’s  can  be  explained  by  the  uneven  distribution  of  Hep  
Par1  in  HCC.
[62] 
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4.CK  7,19  20  (Cytokeratin  7,19,20) 
In  this  study,  CK  7  was  positive  in  100%  cases  of  
Cholangiocarcinoma(Figure 24),  3.33%  0f  Hepatocellular  carcinoma  and  
6.25%  in  Metastatic  Adenocarcinomatous  deposit  in  liver  from  colorectal  
region.  CK  7  was  negative  in  96.67%  cases  of  Hepatocellular  carcinoma  
and  93.75%  cases  of  Metastatic  Adenocarcinomatous  deposit  in  liver  from  
colorectal  region. 
In  this  study,  CK  19  was  positive  in  35.71%  cases  of  Cholangiocarcinoma  
(Figure 25)and  62.50%  in  Metastatic  Adenocarcinomatous  deposit  in  liver  
from  colorectal  region(Figure 22).  CK  19  was  negative  in  100%  cases  in  
Hepatocellular  carcinoma,  64.29%  cases  in  Cholangiocarcinoma  and  37.50%  
in  Metastatic  Adenocarcinomatous  deposit  in  liver  from  colorectal  region. 
In  this  study,  CK  20  was  positive  only    in  87.50%  cases  of  Metastatic  
Adenocarcinomatous  deposit  in  liver  from  colorectal  region(Figure 23).  CK  
20  was  negative  in  100%  cases  of  Hepatocellular  carcinoma  and  
Cholangiocarcinoma  with  12.50%  cases  of  Metastatic  Adenocarcinomatous  
deposit  in  liver  from  colorectal  region. 
Shimonoshi  et  al  concluded  in  his  study  in  2000  that  CK  7,19  and  20  are  
useful  to  differentiate  intrahepatic  cholangiocarcinoma  from  metastatic  
adenocarcinomas  in  liver  from  colorectal  regions;  it  also  indicates  the  
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primary  focus  of  metastatic  adenocarcinomas  in  livers.  In  his  study  CK  7  
was  positive  in  97%  and  CK  19  was  in  92%  cases  of  Intrahepatic  
Cholangiocarcinoma.  CK  20  was  positive  in  81%  of  metastatic  
adenocarcinomas   in   liver   from  colorectal  region.  The  expression  of  CK 19  
in  intrahepatic  cholangiocarcinoma was  decreases  with  the  differentiation  of  
the  tumour.  The  positivity  of  CK 19  was  less  in  moderately  and  poorly  
differentiated  cholangiocarcinomas  compared  to  well  differentiated  
cholangiocarcinoma.  
[42] 
These  results  suggest  that  reactivity  of  bile  duct–type  cytokeratin  was 
reduced  or  lost  in  a  small  number  of cholangiocarcinomas  during  neoplastic 
transformation  or  tumor  development.
[48]
 
Rullier  A  et  al  in  his  study  revealed  that  CK  7  was  positive  in  100%  and  
Ck  20  was  47.36%  in  Intrahepatic  Cholangiocarcinoma.  In  metastatic  
adenocarcinoma  CK  20  was  100%  and  CK  7  was  24%.
[72] 
Bayrak  et  al  in  his  study  stated  the  CK  20  negative  cases  of  colorectal  
adenocarcinoma  can  be  confirmed  by  CDX2.
[73] 
TISSUE  MICRO  ARRAY 
The  advantages  of  manually  made  tissue  micro  array  in  our  study  is  of:   
 Low  cost 
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 Less  time  consuming 
 Less  amount  of  IHC  markers 
 Large  number  of  cases  can  be  done  in  short  time 
Shebl  et  al    made    1mm    cores    in    their    study    using    mechanical    
pencil    tip    and  advantages  of  this  size  are  easy  to  sample  from  donor  
blocks  and  there  is  no  splitting  artifacts  in  the  hot  water  bath  during  
sectioning.
[58] 
In  our  study  we  had  also  used  1.0mm  core  size  and  the  results  were  the  
same. 
Chang  Hwan  Choi  et  al  in  his  study  stated  that  the  core  loss  in  manual  
TMA  array  is  3%  and  in  our  study  was  6%.  
[57] 
 
  Mohamed  A  Elkablawy  et  al  used  radio  antenna  to  make  cores  of  size  
2,3,4mm  size  and  they  states  that  the  larger  the  core  size,  the  blocks  will  
be  uniform,  there  will  be  more  stability  of  cores  in  the  block  and  no  loss  
of  cores  during  cutting  and  sectioning
[59]
. 
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SUMMARY  AND  CONCLUSION 
The  study  was  carried  out  in  the  Department  of  Pathology,  Govt.Stanley  
Medical    College,  over  a  period  of  three  years  from  July  2012  to  June  
2015  after  obtaining  the  approval  from  Institutional  Human  Ethical  
Committee  (IHEC)  of  Govt.  Stanley  Medical  College,  Chennai. 
1)  Total  number  of  cases  studied  were  60,  which  included  30  cases  of  
Hepatocellular  carcinoma(11-well  differentiated,3-moderately  differentiated,16-
poorly  differentited),  14  cases  of  Intrahepatic  cholangiocarcinoma  and  16  
cases  of    Metastatic  Adenocarcinomatous  deposit  in  liver  from  colorectal  
region. 
In  this  study  we  prepared  manual  tissue  microarray  blocks  from  the  selected  
liver  specimens  fulfilling  the  inclusion  and  exclusion  criteria. 
TMA  blocks  are  sectioned  and  Immunohistochemistry  is  done  using  Hep  
par1,  CK  7, 19  and  20  to  differentiate  Hepatocellular  carcinoma,  Intrahepatic  
Cholangiocarcinoma  and  Metastatic  Adenocarcinomatous  deposit  in  liver  
from  colorectal  region. 
2)  Incidence  of  HCC,  ICC  and Metastatic  adenocarcinomatous  deposit  in  
liver  fron  colorectal  region was  high  between  51  to  70  years. 
3) Incidence  of  HCC  was  high  compared  other  tumours. 
4) There  was  only  a  single  case  of  HCC  below  30  years. 
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5)  The  mean  age  incidence  of  Hepatocellular  carcinoma  was  51.63  years,  
Intrahepatic  cholangiocarcinoma  was  57.43  years  and  Metastatic  
Adenocarcinomatous  deposit  in  liver  was  63.19  years. 
6)  Incidence  of  HCC  was  high  in  both  genders. 
7) Out  of  30  cases  of  hepatocellular  carcinoma,    11  were  well  
differentiated,  3  were  moderately  differentiated  and  16  were  poorly  
differentiated  hepatocellular  carcinomas. 
8)  Out  of  30  cases  of  Hepatocellular  carcinoma,  24  cases  were  positive  for  
Hep  par1  and  6  cases  were  negative  for  Hep  par1.  Hep  par1  was  negative  
for  100%  cases  of  Intrahepatic  Cholangiocarcinoma  and  Metastatic  
Adenocarcinomatous  Deposit  in  liver  from  colorectal  region. 
9) CK  7  was  positive  in  100%  cases  of  Cholangiocarcinoma,  3.33%  0f  
Hepatocellular  carcinoma  and  6.25%  in  Metastatic  Adenocarcinomatous  
deposit  in  liver  from  colorectal  region.  CK  7  was  negative  in  96.67%  cases  
of  Hepatocellular  carcinoma  and  93.75%  cases  of  Metastatic  
Adenocarcinomatous  deposit  in  liver  from  colorectal  region. 
10) CK  19  was  positive  in  35.71%  cases  of  Cholangiocarcinoma  and  
62.50%  in  Metastatic  Adenocarcinomatous  deposit  in  liver  from  colorectal  
region.  CK  19  was  negative  in  100%  cases  in  Hepatocellular  carcinoma,  
64.29%  cases  in  Cholangiocarcinoma  and  37.50%  in  Metastatic  
Adenocarcinomatous  deposit  in  liver  from  colorectal  region. 
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11)  CK  20  was  positive  only    in  87.50%  cases  of  Metastatic  
Adenocarcinomatous  deposit  in  liver  from  colorectal  region.  CK  20  was  
negative  in  100%  cases  of  Hepatocellular  carcinoma  and  
Cholangiocarcinoma  with  12.50%  cases  of  Metastatic  Adenocarcinomatous  
deposit  in  liver  from  colorectal  region. 
By  the  end  of  this  study  we  conclude  that  manual  TMA  technique  is  
superior  to  conventional  technique  of    Immunohistochemistry  and  automated  
Micro  arrayer  ---instruments  in  terms  of  cost,  time  consumption,  amount  of  
reagents  used  and  preservation  of  tissue  of  interest. 
Using  this  panel  of  markers-Hep  par1,  CK  7,CK  19  and  CK  20  we  can  
differentiate  Hepatocellular  carcinoma,  Intrahepatic  Cholangiocarcinoma  and  
Metastatic  Adenocarcinomatous  deposit  in  liver  from  colorectal  region.  The  
diagnosis  of  these  malignancies  is  very  important  because  the  treatment  
protocols  differ  for  each  of  these  malignancies.     
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FIGURES 
 
 
Fig  8  Gross  picture  of  Hepatocellular  carcinoma  involving  segment  of  
liver 
 
  Fig  9  Gross  picture  of  Hepatocellular  carcinoma  involving  whole  lobe 
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Fig  10  Gross  picture  of  Cholangiocarcinoma 
 
 
 
Fig  11  H  &  E  picture  of  Well  Differentiated  Hepatocellular  
Carcinoma(10 X  View) 
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Fig  12  H  &  E  picture  of  Moderately  Differentiated  Hepatocellular  
Carcinoma(40 X View) 
 
 
 
Fig  13  H  &  E  picture  of  Poorly  Differentiated  Hepatocellular  
Carcinoma(40 X View) 
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Fig  14  H  &  E  picture  of  Cholangiocarcinoma(40 X View) 
 
 
 
Fig  15  H  &  E  picture  of  Metastatic  Adenocarcinoma  deposit  in  Liver 
( 10 X View) 
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Fig  16  Bone  marrow  aspiration  needle  (16 gauge used)  for  taking  core  
from  donor  block 
 
Fig 17 TMA Slides( H & E, IHC) 
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Fig  18 TMA  BLOCK  1 
                                                 
                                                                               
 
Fig  19  H  &  E  picture  of  TMA  Core (10 X View) 
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Fig  20  CK 20 control positivity  in Colonic Adenocarcinoma(10 X View) 
 
 
 
Fig 21  Hep Par1 positivity in Well differentiated HCC(6 + positivity) 
- 10 X View 
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Fig  22  CK  19  Positivity  in  Metastatic  Adenocarcinomatous  deposit 
                                   (10 X View) 
 
 
 
Fig  23   CK  20    Positivity  in  Metastatic  Adenocarcinomatous  deposit 
                                      (10 X View) 
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Fig  24  CK  7 Positivity in Intrahepatic Cholangiocarcinoma (10 X View)  
 
Fig  25-  CK 19  Positivity in Intrahepatic Cholangiocarcinoma 
                        (10 X View) 
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Fig 26    Hep Par1 Positivity(5+) in Well differentiated Hepatocellular 
Carcinoma( 40 X View) 
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MASTER CHART 
 
S.No 
Biopsy 
Number Age Sex 
Histological 
Diagnosis Grade 
Hep 
Par1 CK 7 CK 19 CK 20 
1 6708/14 55 Male Hilar Cholangio Carcinoma   Negative Positive Positive Negative 
2 6616/14 65 Male Hepatocellular Carcinoma PD 2+  Positive Negative Negative 
3 5952/14 60 Female Hepatocellular Carcinoma MD 5+ Negative Negative Negative 
4 5324/14 75 Male 
Metastatic 
Adenocarcinomatous Deposit   Negative Negative Positive Negative 
5 4779/14 60 Female Hepatocellular Carcinoma PD 2+ Negative Negative Negative 
6 4561/14 62 Male Hilar Cholangio Carcinoma   Negative  Positive Negative Negative 
7 3889/14 43 Female Hilar Cholangio Carcinoma   Negative  Positive Positive Negative 
8 3756/14 73 Male 
Metastatic 
Adenocarcinomatous Deposit   Negative Negative Positive Positive 
9 3408/14 41 Female Hepatocellular Carcinoma PD 1+ Negative Negative Negative 
10 3355/14 35 Male Hilar Cholangio Carcinoma   Negative  Positive Negative Negative 
11 3025/14 62 Male Hepatocellular Carcinoma PD 2+ Negative Negative Negative 
12 2915/14 78 Male 
Metastatic 
Adenocarcinomatous Deposit   Negative Negative Negative Positive 
13 2815/14 65 Male Hilar Cholangio Carcinoma   Negative  Positive Negative Negative 
14 2341/14 52 Male Hilar Cholangio Carcinoma   Negative  Positive Positive Negative 
15 2209/14 43 Male Hilar Cholangio Carcinoma   Negative  Positive Negative Negative 
16 2199/14 60 Female 
Metastatic 
Adenocarcinomatous Deposit   Negative Negative Negative Positive 
17 2166/14 27 Female Hepatocellular Carcinoma PD Negative Negative Negative Negative 
18 1979/14 57 Male Hilar Cholangio Carcinoma   Negative  Positive Positive Negative 
19 954/14 50 Male Hepatocellular Carcinoma WD 5+ Negative Negative Negative 
20 903/14 80 Male Hilar Cholangio Carcinoma   Negative  Positive Negative Negative 
21 773/14 35 Female Hepatocellular Carcinoma PD Negative Negative Negative Negative 
22 754/14 63 Male 
Metastatic 
Adenocarcinomatous Deposit   Negative Negative Negative Positive 
23 482/14 60 Male Hepatocellular Carcinoma WD 6+ Negative Negative Negative 
24 6586/13 60 Female 
Metastatic 
Adenocarcinomatous Deposit   Negative Negative Positive Positive 
25 4628/13 50 Female 
Metastatic 
Adenocarcinomatous Deposit   Negative Negative Positive Positive 
26 4610/13 80 Male 
Metastatic 
Adenocarcinomatous Deposit   Negative Negative Positive Positive 
27 4446/13 53 Male Hilar Cholangio Carcinoma   Negative  Positive Positive Negative 
28 4010/13 45 Female Hepatocellular Carcinoma PD 1+ Negative Negative Negative 
29 3799/13 55 Male Hepatocellular Carcinoma WD 6+ Negative Negative Negative 
30 3200/13 42 Male Hepatocellular Carcinoma PD Negative Negative Negative Negative 
31 3017/13 57 Male Hepatocellular Carcinoma MD 6+ Negative Negative Negative 
32 2820/13 57 Male Hepatocellular Carcinoma WD 6+ Negative Negative Negative 
33 2488/13 60 Female Hepatocellular Carcinoma WD 6+ Negative Negative Negative 
34 2643/13 55 Male Metastatic   Negative Negative Positive Positive 
cx 
 
Adenocarcinomatous Deposit 
35 2278/13 60 Female Hilar Cholangio Carcinoma   Negative Positive Negative Negative 
36 1376/13 70 Female 
Metastatic 
Adenocarcinomatous Deposit   Negative Negative Positive Positive 
37 1323/13 68 Female 
Metastatic 
Adenocarcinomatous Deposit   Negative Negative Negative Positive 
38 1182/13 66 Male Hepatocellular Carcinoma PD 2+ Negative Negative Negative 
39 703/15 89 Male 
Metastatic 
Adenocarcinomatous Deposit   Negative Negative Positive Positive 
40 1091/15 75 Male Hilar Cholangio Carcinoma   Negative Positive Negative Negative 
41 6553/13 45 Female Hepatocellular Carcinoma MD 3+ Negative Negative Negative 
42 1081/13 59 Female Hepatocellular Carcinoma PD Negative Negative Negative Negative 
43 868/13 55 Male 
Metastatic 
Adenocarcinomatous Deposit   Negative Negative Positive Positive 
44 673/13 73 Male Hepatocellular Carcinoma PD 2+ Negative Negative Negative 
45 477/13 46 Male Hepatocellular Carcinoma WD 5+ Negative Negative Negative 
46 6105/12 61 Male Hilar Cholangio Carcinoma   Negative Positive Negative Negative 
47 6017/12 58 Male Hepatocellular Carcinoma PD Negative Negative Negative Negative 
48 4063/12 52 Male 
Metastatic 
Adenocarcinomatous Deposit   Negative Positive Positive Negative 
49 3784/12 50 Male Hepatocellular Carcinoma PD 2+ Negative Negative Negative 
50 3602/12 53 Male Hepatocellular Carcinoma WD 6+ Negative Negative Negative 
51 2829/12 65 Male Hepatocellular Carcinoma WD 4+ Negative Negative Negative 
52 1475/12 53 Male Hepatocellular Carcinoma PD Negative Negative Negative Negative 
53 1207/12 40 Female Hepatocellular Carcinoma PD 2+ Negative Negative Negative 
54 1166/12 37 Male Hepatocellular Carcinoma PD 1+ Negative Negative Negative 
55 1052/12 45 Female Hepatocellular Carcinoma WD 5+ Negative Negative Negative 
56 564/12 38 Male Hepatocellular Carcinoma WD 5+ Negative Negative Negative 
57 339/12 51 Male 
Metastatic 
Adenocarcinomatous Deposit   Negative Negative Positive Positive 
58 6084/13 32 Female 
Metastatic 
Adenocarcinomatous Deposit   Negative Negative Negative Positive 
59 6553/13 45 Female Hepatocellular Carcinoma WD 6+ Negative Negative Negative 
60 5282/13 63 Male Hilar Cholangio Carcinoma   Negative Positive Negative Negative 
 
 
 
